Risankizumab safe, effective at 52 weeks for psoriatic arthritis
by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe
Updated on: June 01,2024
7

Risankizumab safe, effective at 52 weeks for psoriatic arthritis
by Lori SolomonRisankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently publishe
Updated on:June 01,2024
7
